Navigation Links
MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008

VALENCIA, Calif., Feb. 28 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2007 fourth quarter financial results on Tuesday, March 4, 2008 at 7:00 a.m. ET.

Management of the Company will host a conference call to discuss the fourth quarter financial results, clinical progress and other Company developments at 9:00 a.m. ET on Tuesday, March 4, 2008. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Dick Anderson and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 566-5775 or (210) 234-0004. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (866) 396-7637 or (203) 369-0522. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. MannKind to Present at the Wachovia 2008 Healthcare Conference
3. MannKind to Present at the Piper Jaffray Healthcare Conference
4. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
5. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
6. MannKind to Present at the UBS Global Life Sciences Conference
7. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
8. Insulet Corporation to Report Fourth Quarter and Full Year 2007 Financial Results on Monday, March 17
9. Pharmion Corporation Announces 2007 Operating Results
10. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
11. VLST Corporation Announces Board and Executive Management Appointments
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... were featured on AngelList early in their initial angel funding process. Now, they ... for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... The United ... recipient of the 2016 USGA Green Section Award. Presented annually since 1961, the USGA ... his or her work with turfgrass. , Clarke, of Iselin, N.J., is ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... York on Wednesday, December 2 at 9:30 a.m. ET/6:30 ... CEO, will provide a corporate overview. th Annual ... 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola , ... corporate overview. --> th Annual Oppenheimer Healthcare Conference ...
Breaking Biology Technology:
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
Breaking Biology News(10 mins):